Search Results

Oxford Nanopore Technologies announced the launch of a new Pharmacogenomics Beta Program to advance personalised medicine, combining Twist Bioscience’s next generation sequencing target enrichment technology with Oxford Nanopore’s sequencing platform.

Oxford Nanopore Technologies plc, the company delivering a new generation of nanopore-based molecular sensing technology, and SeqOne, the leading AI-driven genomic decision support software, announced a new partnership enabling end-to-end analytical workflows from sample to report, focusing on rare diseases in the short-term and oncology in the longer-term.

Oxford Nanopore Technologies announced the early access launch of its all-in-one desk top sequencing device, the PromethION 2 Integrated to complete its PromethION product range.

Oxford Nanopore Technologies plc, the company delivering a new generation of nanopore-based molecular sensing technology, and Saphetor, the next generation sequencing data analysis company, announce a new partnership to support the comprehensive analysis of nanopore sequencing data and to enable end-to-end workflows.

Mayo Clinic and Oxford Nanopore Technologies, the company delivering a new generation of nanopore-based molecular sensing technology, unveiled a multi-year joint development collaboration to develop new clinical tests for diseases and improve patient care.

Researchers at The University of Queensland are harnessing the latest sequencing technology developed by UK-based biotech Oxford Nanopore Technologies to analyse mRNA vaccines and therapies.

Oxford Nanopore Technologies plc and Fabric Genomics announced a new collaboration to develop a scalable software solution for the end-to-end analysis and clinical reporting of rich genomic data.

Oxford Nanopore and Day Zero Diagnostics announced a collaboration to develop an end-to-end solution for the diagnosis of bloodstream infections, a leading cause of sepsis.